Evaluation of Medical Countermeasures Against Ebolaviruses in Nonhuman Primate Models
- PMID: 28573630
- DOI: 10.1007/978-1-4939-7116-9_24
Evaluation of Medical Countermeasures Against Ebolaviruses in Nonhuman Primate Models
Abstract
Several ebolavirus species, with varying lethality rates, have caused sporadic outbreaks in Africa resulting in human disease. Ebolaviruses also have the potential for use as biological weapons. Currently, there are no licensed vaccines or therapeutics to respond to outbreaks or deliberate misuse of ebolaviruses. Vaccine or therapeutic efficacy testing of medical countermeasures against ebolaviruses requires an animal model of disease; in vitro testing in cell culture cannot reproduce the complicated balance between host-pathogen interactions required for the ultimate licensure of a countermeasure. Depending on the target of the countermeasure, demonstration of efficacy in the nonhuman primate ebolavirus disease models will most likely be required before licensure. Here, we describe the selection and use of nonhuman primates for vaccine and therapeutic studies against ebolaviruses.
Keywords: Bundibugyo; Ebola; Ebolavirus; Nonhuman primate model; Sudan; Therapeutic; Vaccine; Zaire.
Similar articles
-
Animal models for ebolavirus countermeasures discovery: what defines a useful model?Expert Opin Drug Discov. 2015 Jul;10(7):685-702. doi: 10.1517/17460441.2015.1035252. Epub 2015 May 25. Expert Opin Drug Discov. 2015. PMID: 26004783 Review.
-
Ebola virus vaccines - reality or fiction?Expert Rev Vaccines. 2016 Nov;15(11):1421-1430. doi: 10.1080/14760584.2016.1178068. Epub 2016 May 9. Expert Rev Vaccines. 2016. PMID: 27078187 Free PMC article. Review.
-
Assessing Antiviral Countermeasures Using Mouse Models of Ebolavirus Infection.Methods Mol Biol. 2017;1628:273-282. doi: 10.1007/978-1-4939-7116-9_22. Methods Mol Biol. 2017. PMID: 28573628
-
Evaluation of Vaccines and Therapeutics Against Ebolaviruses in the Domestic Ferret.Methods Mol Biol. 2025;2877:281-295. doi: 10.1007/978-1-0716-4256-6_19. Methods Mol Biol. 2025. PMID: 39585628
-
Bundibugyo ebolavirus Survival Is Associated with Early Activation of Adaptive Immunity and Reduced Myeloid-Derived Suppressor Cell Signaling.mBio. 2021 Aug 31;12(4):e0151721. doi: 10.1128/mBio.01517-21. Epub 2021 Aug 10. mBio. 2021. PMID: 34372693 Free PMC article.
Cited by
-
Natural history of nonhuman primates after conjunctival exposure to Ebola virus.Sci Rep. 2023 Mar 13;13(1):4175. doi: 10.1038/s41598-023-31027-7. Sci Rep. 2023. PMID: 36914721 Free PMC article.
-
Virus inoculation and treatment regimens for evaluating anti-filovirus monoclonal antibody efficacy in vivo.Biosaf Health. 2019 Jun;1(1):6-13. doi: 10.1016/j.bsheal.2019.02.004. Epub 2019 Mar 1. Biosaf Health. 2019. PMID: 32835206 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical